Zhuhai Sailong Pharmaceutical Co Ltd (002898) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zhuhai Sailong Pharmaceutical Co Ltd (002898) has a cash flow conversion efficiency ratio of -0.062x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-28.66 Million ≈ $-4.19 Million USD) by net assets (CN¥460.47 Million ≈ $67.38 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Zhuhai Sailong Pharmaceutical Co Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Zhuhai Sailong Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Zhuhai Sailong Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Zhuhai Sailong Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zhuhai Sailong Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ButOne Information Corp XiAn
SHG:600455
|
0.433x |
|
SmartRent Inc
NYSE:SMRT
|
-0.009x |
|
Neto M.E Holdings Ltd
TA:NTO
|
-0.105x |
|
HansBiomed Corporation
KQ:042520
|
0.036x |
|
Auden Techno
TW:3138
|
0.013x |
|
Dream Office Real Estate Investment Trust
TO:D-UN
|
-0.004x |
|
Azkoyen
MC:AZK
|
0.141x |
|
Panca Budi Idaman Tbk PT
JK:PBID
|
0.019x |
Annual Cash Flow Conversion Efficiency for Zhuhai Sailong Pharmaceutical Co Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of Zhuhai Sailong Pharmaceutical Co Ltd from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see 002898 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥384.15 Million ≈ $56.21 Million |
CN¥19.06 Million ≈ $2.79 Million |
0.050x | +163.74% |
| 2024-12-31 | CN¥499.28 Million ≈ $73.06 Million |
CN¥-38.86 Million ≈ $-5.69 Million |
-0.078x | -216.81% |
| 2023-12-31 | CN¥535.88 Million ≈ $78.42 Million |
CN¥35.71 Million ≈ $5.23 Million |
0.067x | +148.30% |
| 2022-12-31 | CN¥526.35 Million ≈ $77.02 Million |
CN¥14.12 Million ≈ $2.07 Million |
0.027x | -57.35% |
| 2021-12-31 | CN¥563.66 Million ≈ $82.48 Million |
CN¥35.46 Million ≈ $5.19 Million |
0.063x | +21040.16% |
| 2020-12-31 | CN¥587.00 Million ≈ $85.90 Million |
CN¥174.69K ≈ $25.56K |
0.000x | +100.42% |
| 2019-12-31 | CN¥659.02 Million ≈ $96.44 Million |
CN¥-46.52 Million ≈ $-6.81 Million |
-0.071x | -1507.08% |
| 2018-12-31 | CN¥663.54 Million ≈ $97.10 Million |
CN¥3.33 Million ≈ $487.06K |
0.005x | -96.35% |
| 2017-12-31 | CN¥618.64 Million ≈ $90.53 Million |
CN¥85.13 Million ≈ $12.46 Million |
0.138x | -55.48% |
| 2016-12-31 | CN¥254.45 Million ≈ $37.23 Million |
CN¥78.65 Million ≈ $11.51 Million |
0.309x | +38.92% |
| 2015-12-31 | CN¥213.20 Million ≈ $31.20 Million |
CN¥47.44 Million ≈ $6.94 Million |
0.223x | -39.11% |
| 2014-12-31 | CN¥140.55 Million ≈ $20.57 Million |
CN¥51.36 Million ≈ $7.52 Million |
0.365x | -36.90% |
| 2013-12-31 | CN¥111.97 Million ≈ $16.38 Million |
CN¥64.84 Million ≈ $9.49 Million |
0.579x | -- |
About Zhuhai Sailong Pharmaceutical Co Ltd
Sailong Pharmaceutical Group Co.,Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. The company offers esomeprazole sodium, ornithine aspartate, thymus, argatroban, tigecycline, monosialotetrahexose ganglioside sodium, cerebroprotein hydrolysate, milrinone, parecoxib sodium, tranexamic acid, clindamycin phosphate, pan… Read more